3qtk - Revision history

OCA at 11:57, 14 March 2024

OCA — Thu, 14 Mar 2024 11:57:33 GMT

←Older revision		Revision as of 11:57, 14 March 2024
Line 3:		Line 3:
	<StructureSection load='3qtk' size='340' side='right'caption='[[3qtk]], [[Resolution\|resolution]] 1.85Å' scene=''>		<StructureSection load='3qtk' size='340' side='right'caption='[[3qtk]], [[Resolution\|resolution]] 1.85Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[3qtk]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QTK OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3QTK FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[3qtk]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QTK OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3QTK FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=TFA:TRIFLUOROACETIC+ACID'>TFA</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.849Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=TFA:TRIFLUOROACETIC+ACID'>TFA</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3qtk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3qtk OCA], [https://pdbe.org/3qtk PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3qtk RCSB], [https://www.ebi.ac.uk/pdbsum/3qtk PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3qtk ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3qtk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3qtk OCA], [https://pdbe.org/3qtk PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3qtk RCSB], [https://www.ebi.ac.uk/pdbsum/3qtk PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3qtk ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
-	[[https://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN]] Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:[https://omim.org/entry/603933 603933]]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.	+	[https://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN] Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:[https://omim.org/entry/603933 603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
	== Function ==		== Function ==
-	[[https://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN]] Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.<ref>PMID:11427521</ref> <ref>PMID:15520188</ref> <ref>PMID:16489009</ref>	+	[https://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN] Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.<ref>PMID:11427521</ref> <ref>PMID:15520188</ref> <ref>PMID:16489009</ref>
-	~~<div style="background-color:#fffaf0;">~~	+
-	~~== Publication Abstract from PubMed ==~~	+
-	Efficient access: The 204-residue covalent-dimer vascular endothelial growth factor (VEGF, see picture) with full mitogenic activity was prepared from three unprotected peptide segments by one-pot native chemical ligations. The covalent structure of the synthetic VEGF was confirmed by precise mass measurement, and the three-dimensional structure of the synthetic protein was determined by high-resolution X-ray crystallography.	+
-		+
-	Total chemical synthesis of biologically active vascular endothelial growth factor.,Mandal K, Kent SB Angew Chem Int Ed Engl. 2011 Aug 22;50(35):8029-33. doi: 10.1002/anie.201103237. , Epub 2011 Jul 8. PMID:21744452<ref>PMID:21744452</ref>	+
-		+
-	~~From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>~~	+
-	~~</div>~~	+
-	~~<div class="pdbe-citations 3qtk" style="background-color:#fffaf0;"></div~~>	+

	==See Also==		==See Also==
Line 27:		Line 19:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Kent~~, S B.H~~]]	+	[[Category: Kent SBH]]
-	[[Category: Mandal, K]]	+	[[Category: Mandal K]]
-	~~[[Category: Covalent dimer]]~~	+
-	~~[[Category: Cysteine knot protein]]~~	+
-	~~[[Category: Growth factor]]~~	+
-	~~[[Category: Hormone]]~~	+
-	~~[[Category: Human vegf-a]]~~	+
-	~~[[Category: X-ray crystal structure~~]]	+

OCA at 06:23, 8 June 2022

OCA — Wed, 08 Jun 2022 06:23:12 GMT

←Older revision		Revision as of 06:23, 8 June 2022
Line 1:		Line 1:

	==The crystal structure of chemically synthesized VEGF-A==		==The crystal structure of chemically synthesized VEGF-A==
-	<StructureSection load='3qtk' size='340' side='right' caption='[[3qtk]], [[Resolution\|resolution]] 1.85Å' scene=''>	+	<StructureSection load='3qtk' size='340' side='right'caption='[[3qtk]], [[Resolution\|resolution]] 1.85Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[3qtk]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QTK OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=3QTK FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[3qtk]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QTK OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3QTK FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=TFA:TRIFLUOROACETIC+ACID'>TFA</scene></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=TFA:TRIFLUOROACETIC+ACID'>TFA</scene></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=3qtk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3qtk OCA], [~~http~~://pdbe.org/3qtk PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=3qtk RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/3qtk PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=3qtk ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3qtk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3qtk OCA], [https://pdbe.org/3qtk PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3qtk RCSB], [https://www.ebi.ac.uk/pdbsum/3qtk PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3qtk ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
-	[[~~http~~://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN]] Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:[~~http~~://omim.org/entry/603933 603933]]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.	+	[[https://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN]] Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:[https://omim.org/entry/603933 603933]]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
	== Function ==		== Function ==
-	[[~~http~~://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN]] Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.<ref>PMID:11427521</ref> <ref>PMID:15520188</ref> <ref>PMID:16489009</ref>	+	[[https://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN]] Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.<ref>PMID:11427521</ref> <ref>PMID:15520188</ref> <ref>PMID:16489009</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 22:		Line 22:

	==See Also==		==See Also==
-	*[[~~Vascular Endothelial Growth Factor~~\|~~Vascular Endothelial Growth Factor~~]]	+	*[[VEGF 3D Structures\|VEGF 3D Structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Large Structures]]
	[[Category: Kent, S B.H]]		[[Category: Kent, S B.H]]
	[[Category: Mandal, K]]		[[Category: Mandal, K]]

OCA at 14:18, 4 August 2016

OCA — Thu, 04 Aug 2016 14:18:38 GMT

←Older revision		Revision as of 14:18, 4 August 2016
Line 1:		Line 1:
		+
	==The crystal structure of chemically synthesized VEGF-A==		==The crystal structure of chemically synthesized VEGF-A==
	<StructureSection load='3qtk' size='340' side='right' caption='[[3qtk]], [[Resolution\|resolution]] 1.85Å' scene=''>		<StructureSection load='3qtk' size='340' side='right' caption='[[3qtk]], [[Resolution\|resolution]] 1.85Å' scene=''>
Line 4:		Line 5:
	<table><tr><td colspan='2'>[[3qtk]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QTK OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3QTK FirstGlance]. <br>		<table><tr><td colspan='2'>[[3qtk]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QTK OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3QTK FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=TFA:TRIFLUOROACETIC+ACID'>TFA</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=TFA:TRIFLUOROACETIC+ACID'>TFA</scene></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3qtk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3qtk OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3qtk RCSB], [http://www.ebi.ac.uk/pdbsum/3qtk PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3qtk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3qtk OCA], [http://pdbe.org/3qtk PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=3qtk RCSB], [http://www.ebi.ac.uk/pdbsum/3qtk PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=3qtk ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 18:		Line 19:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
		+	<div class="pdbe-citations 3qtk" style="background-color:#fffaf0;"></div>

	==See Also==		==See Also==

OCA at 11:00, 19 December 2014

OCA — Fri, 19 Dec 2014 11:00:59 GMT

←Older revision		Revision as of 11:00, 19 December 2014
Line 1:		Line 1:
-	~~{{STRUCTURE_3qtk\| PDB=3qtk \| SCENE= }}~~	+	==The crystal structure of chemically synthesized VEGF-A==
-	===The crystal structure of chemically synthesized VEGF-A===	+	<StructureSection load='3qtk' size='340' side='right' caption='[[3qtk]], [[Resolution\|resolution]] 1.85Å' scene=''>
-	~~{{ABSTRACT_PUBMED_21744452}}~~	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[3qtk]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QTK OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3QTK FirstGlance]. <br>
-	==Disease==	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=TFA:TRIFLUOROACETIC+ACID'>TFA</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3qtk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3qtk OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3qtk RCSB], [http://www.ebi.ac.uk/pdbsum/3qtk PDBsum]</span></td></tr>
		+	</table>
		+	== Disease ==
	[[http://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN]] Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:[http://omim.org/entry/603933 603933]]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.		[[http://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN]] Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:[http://omim.org/entry/603933 603933]]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN]] Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.<ref>PMID:11427521</ref> <ref>PMID:15520188</ref> <ref>PMID:16489009</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Efficient access: The 204-residue covalent-dimer vascular endothelial growth factor (VEGF, see picture) with full mitogenic activity was prepared from three unprotected peptide segments by one-pot native chemical ligations. The covalent structure of the synthetic VEGF was confirmed by precise mass measurement, and the three-dimensional structure of the synthetic protein was determined by high-resolution X-ray crystallography.

-	~~==Function==~~	+	Total chemical synthesis of biologically active vascular endothelial growth factor.,Mandal K, Kent SB Angew Chem Int Ed Engl. 2011 Aug 22;50(35):8029-33. doi: 10.1002/anie.201103237. , Epub 2011 Jul 8. PMID:21744452<ref>PMID:21744452</ref>
-	~~[[http://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN]] Growth factor~~ active ~~in angiogenesis, vasculogenesis and~~ endothelial ~~cell~~ growth. ~~Induces endothelial cell proliferation~~, ~~promotes cell migration~~, ~~inhibits apoptosis and induces permeabilization of blood vessels~~. ~~Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin~~. ~~NRP1~~/~~Neuropilin-1 binds isoforms VEGF-165 and VEGF-145~~. ~~Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways~~, ~~does not activate angiogenesis and inhibits tumor growth~~.~~<ref>~~PMID:~~11427521</ref><ref>PMID:15520188</ref>~~<ref>PMID:~~16489009~~</ref>	+

-	~~==About this Structure==~~	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	~~[[3qtk]] is~~ a ~~6 chain structure~~. ~~Full crystallographic information is available from [http://oca~~.~~weizmann~~.~~ac.il~~/~~oca-bin/ocashort?id=3QTK OCA].~~	+	</div>

	==See Also==		==See Also==
	*[[Vascular Endothelial Growth Factor\|Vascular Endothelial Growth Factor]]		*[[Vascular Endothelial Growth Factor\|Vascular Endothelial Growth Factor]]
-		+	== References ==
-	==~~Reference~~==	+	<references/>
-	~~<ref group="xtra">PMID:021744452</ref>~~<references ~~group="xtra"~~/><~~references~~/>	+	__TOC__
-	[[Category: Kent, S B.H.]]	+	</StructureSection>
-	[[Category: Mandal, K.]]	+	[[Category: Kent, S B.H]]
		+	[[Category: Mandal, K]]
	[[Category: Covalent dimer]]		[[Category: Covalent dimer]]
	[[Category: Cysteine knot protein]]		[[Category: Cysteine knot protein]]

OCA at 20:13, 24 March 2013

OCA — Sun, 24 Mar 2013 20:13:09 GMT

←Older revision		Revision as of 20:13, 24 March 2013
Line 1:		Line 1:
-	[[Image:3qtk.png\|left\|200px]]
-
	{{STRUCTURE_3qtk\| PDB=3qtk \| SCENE= }}		{{STRUCTURE_3qtk\| PDB=3qtk \| SCENE= }}
-
	===The crystal structure of chemically synthesized VEGF-A===		===The crystal structure of chemically synthesized VEGF-A===
		+	{{ABSTRACT_PUBMED_21744452}}

-	~~{{ABSTRACT_PUBMED_21744452}}~~	+	==Disease==
		+	[[http://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN]] Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:[http://omim.org/entry/603933 603933]]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
		+
		+	==Function==
		+	[[http://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN]] Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.<ref>PMID:11427521</ref><ref>PMID:15520188</ref><ref>PMID:16489009</ref>

	==About this Structure==		==About this Structure==
Line 14:		Line 16:

	==Reference==		==Reference==
-	<ref group="xtra">PMID:021744452</ref><references group="xtra"/>	+	<ref group="xtra">PMID:021744452</ref><references group="xtra"/><references/>
	[[Category: Kent, S B.H.]]		[[Category: Kent, S B.H.]]
	[[Category: Mandal, K.]]		[[Category: Mandal, K.]]

OCA at 06:49, 20 October 2012

OCA — Sat, 20 Oct 2012 06:49:31 GMT

←Older revision		Revision as of 06:49, 20 October 2012
Line 8:		Line 8:

	==About this Structure==		==About this Structure==
-	[[3qtk]] is a 6 chain structure ~~of [[Vascular Endothelial Growth Factor]]~~. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QTK OCA].	+	[[3qtk]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QTK OCA].

	==See Also==		==See Also==

OCA at 05:56, 17 October 2012

OCA — Wed, 17 Oct 2012 05:56:59 GMT

←Older revision		Revision as of 05:56, 17 October 2012
Line 5:		Line 5:
	===The crystal structure of chemically synthesized VEGF-A===		===The crystal structure of chemically synthesized VEGF-A===

		+	{{ABSTRACT_PUBMED_21744452}}

	==About this Structure==		==About this Structure==

OCA at 14:24, 25 July 2012

OCA — Wed, 25 Jul 2012 14:24:47 GMT

←Older revision		Revision as of 14:24, 25 July 2012
Line 1:		Line 1:
-	[[Image:3qtk.~~jpg~~\|left\|200px]]	+	[[Image:3qtk.png\|left\|200px]]

-	<!--
-	The line below this paragraph, containing "STRUCTURE_3qtk", creates the "Structure Box" on the page.
-	You may change the PDB parameter (which sets the PDB file loaded into the applet)
-	or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
-	or leave the SCENE parameter empty for the default display.
-	-->
	{{STRUCTURE_3qtk\| PDB=3qtk \| SCENE= }}		{{STRUCTURE_3qtk\| PDB=3qtk \| SCENE= }}

Line 13:		Line 7:

	==About this Structure==		==About this Structure==
-	[[3qtk]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QTK OCA].	+	[[3qtk]] is a 6 chain structure of [[Vascular Endothelial Growth Factor]]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QTK OCA].
		+
		+	==See Also==
		+	*[[Vascular Endothelial Growth Factor\|Vascular Endothelial Growth Factor]]

	==Reference==		==Reference==

OCA at 06:03, 27 July 2011

OCA — Wed, 27 Jul 2011 06:03:49 GMT

←Older revision		Revision as of 06:03, 27 July 2011
Line 1:		Line 1:
-	~~'''Unreleased structure'''~~	+	[[Image:3qtk.jpg\|left\|200px]]

-	The ~~entry 3qtk~~ is ~~ON HOLD~~ ~~until Paper Publication~~	+	<!--
		+	The line below this paragraph, containing "STRUCTURE_3qtk", creates the "Structure Box" on the page.
		+	You may change the PDB parameter (which sets the PDB file loaded into the applet)
		+	or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
		+	or leave the SCENE parameter empty for the default display.
		+	-->
		+	{{STRUCTURE_3qtk\| PDB=3qtk \| SCENE= }}

-	~~Authors: Mandal, K., Kent, S.B.H.~~	+	===The crystal structure of chemically synthesized VEGF-A===

-	~~Description~~: ~~The~~ crystal structure ~~of chemically synthesized VEGF-A~~	+
		+	==About this Structure==
		+	[[3qtk]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QTK OCA].
		+
		+	==Reference==
		+	<ref group="xtra">PMID:021744452</ref><references group="xtra"/>
		+	[[Category: Kent, S B.H.]]
		+	[[Category: Mandal, K.]]
		+	[[Category: Covalent dimer]]
		+	[[Category: Cysteine knot protein]]
		+	[[Category: Growth factor]]
		+	[[Category: Hormone]]
		+	[[Category: Human vegf-a]]
		+	[[Category: X-ray crystal structure]]

OCA at 06:45, 23 March 2011

OCA — Wed, 23 Mar 2011 06:45:49 GMT

←Older revision		Revision as of 06:45, 23 March 2011
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 3qtk is ON HOLD	+	The entry 3qtk is ON HOLD until Paper Publication

	Authors: Mandal, K., Kent, S.B.H.		Authors: Mandal, K., Kent, S.B.H.

	Description: The crystal structure of chemically synthesized VEGF-A		Description: The crystal structure of chemically synthesized VEGF-A